Association between atopic dermatitis and colorectal cancer risk

Chou, Wan-Yun; Lai, Pin-Yu; Hu, Je-Ming; Hsu, Chih-Hsiung; Chen, Yong‐Chen; Tian, Yufeng; You, San–Lin; Hsiao, Cheng–Wen; Chou, Yu‐Ching; Sun, Chien‐An

doi:10.1097/md.0000000000018530

Cited by 16 publications

(14 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Affected epithelial cells can induce type 2 immunity through secretion of thymic stromal lymphopoietin and IL33 ( Gavrilova, 2018 ). Atopic dermatitis has been linked with increased risk for cancers including basal cell and keratinocyte carcinoma, kidney cancer, and colorectal cancer ( Gandini et al, 2016 ; Chou et al, 2020 ; Wang et al, 2020a ). Treatments for atopic dermatitis that target type 2 inflammation are already in place, and more are being investigated.…”

Section: Type 2 Inflammation May Be a Shared Process Of Tumorigenesis Driven By Autoimmunity And Other Chronic Inflammatory Conditionsmentioning

confidence: 99%

Autoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation

Chen

2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Recent epidemiological studies have found an alarming trend of increased cancer incidence in adults younger than 50 years of age and projected a substantial rise in cancer incidence over the next 10 years in this age group. This trend was exemplified in the incidence of non-cardia gastric cancer and its disproportionate impact on non-Hispanic white females under the age of 50. The trend is concurrent with the increasing incidence of autoimmune diseases in industrialized countries, suggesting a causal link between the two. While autoimmunity has been suspected to be a risk factor for some cancers, the exact mechanisms underlying the connection between autoimmunity and cancer remain unclear and are often controversial. The link has been attributed to several mediators such as immune suppression, infection, diet, environment, or, perhaps most plausibly, chronic inflammation because of its well-recognized role in tumorigenesis. In that regard, autoimmune conditions are common causes of chronic inflammation and may trigger repetitive cycles of antigen-specific cell damage, tissue regeneration, and wound healing. Illustrating the connection between autoimmune diseases and cancer are patients who have an increased risk of cancer development associated with genetically predisposed insufficiency of cytotoxic T lymphocyte-associated protein 4 (CTLA4), a prototypical immune checkpoint against autoimmunity and one of the main targets of cancer immune therapy. The tumorigenic process triggered by CTLA4 insufficiency has been shown in a mouse model to be dependent on the type 2 cytokines interleukin-4 (IL4) and interleukin-13 (IL13). In this type 2 inflammatory milieu, crosstalk with type 2 immune cells may initiate epigenetic reprogramming of epithelial cells, leading to a metaplastic differentiation and eventually malignant transformation even in the absence of classical oncogenic mutations. Those findings complement a large body of evidence for type 1, type 3, or other inflammatory mediators in inflammatory tumorigenesis. This review addresses the potential of autoimmunity as a causal factor for tumorigenesis, the underlying inflammatory mechanisms that may vary depending on host-environment variations, and implications to cancer prevention and immunotherapy.

show abstract

Section: Type 2 Inflammation May Be a Shared Process Of Tumorigenesis Driven By Autoimmunity And Other Chronic Inflammatory Conditionsmentioning

confidence: 99%

Autoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation

Chen

2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…However, the eventual presence of co-morbidities can induce changes in cancer genetics, molecular, and clinical outcomes, complicating both epidemiologic and mechanistic studies. In fact, several genes and related products involved in highly prevalent illnesses strongly concur to cancer heterogeneity, i.e., hypertension [ 14 , 15 , 16 ], diabetes [ 17 ], allergies [ 18 , 19 , 20 , 21 ] and inflammatory chronic diseases [ 22 , 23 , 24 ].…”

Section: Introductionmentioning

confidence: 99%

Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer

Ottaiano

Caraglia

Mauro

et al. 2020

Cancers

View full text Add to dashboard Cite

Genetic dynamics underlying cancer progression are largely unknown and several genes involved in highly prevalent illnesses (e.g., hypertension, obesity, and diabetes) strongly concur to cancer phenotype heterogeneity. To study genotype-phenotype relationships contributing to the mutational evolution of colorectal cancer (CRC) with a focus on liver metastases, we performed genome profiling on tumor tissues of CRC patients with liver metastatic disease and no co-morbidities. We studied 523 cancer-related genes and tumor-immune microenvironment characteristics in primary and matched metastatic tissues. We observed a loss of KRAS and SMAD4 alterations and a high granzyme-B+ T-cell infiltration when the disease did not progress. Conversely, gain in KRAS, PIK3CA and SMAD4 alterations and scarce granzyme-B+ T-cells infiltration were observed when the tumor evolved towards a poly-metastatic spread. These findings provide novel insights into the identification of tumor oligo-metastatic status, indicating that some genes are on a boundary line between these two clinical settings (oligo- vs. poly-metastatic CRC). We speculate that the identification of these genes and modification of their evolution could be a new approach for anti-cancer therapeutic strategies.

show abstract

“…The usefulness of record linkage to conduct pharmacoepidemiological studies in the area of cancer is supported by experiences gained in other clinical areas where this method has been used for many years; studies have, for example, used Scottish data to determine the effectiveness and safety of cardiovascular drugs; evaluate the effects of in-utero exposure to antihypertensive drugs on neonatal outcomes; and calculate the cost burden of Clostridium difficile infections, to name just a few. [37–39]…”

Section: Discussionmentioning

confidence: 99%

Opportunities and challenges when using record linkage of routinely collected electronic health care data to evaluate outcomes of systemic anti-cancer treatment in clinical practice

Mueller

Laskey

Baillie

et al. 2021

Preprint

View full text Add to dashboard Cite

Objectives: To discuss the opportunities and challenges when applying an electronic record linkage methodology with respect to systemic anti-cancer therapy, and to highlight some of the potential pitfalls spanning the entire breadth and depth of the research process. Design: Retrospective cohort studies using routinely collected, administrative health data. Setting: Scotland Results: Studies conducted to-date have indicated that record linkage of routinely collected data to determine outcomes of treatment with cancer medicines is feasible, albeit currently within certain limits. While the general description of patient populations and the calculation of median overall survival are well supported, prevailing issues with combining data across regional boundaries and the limited availability of some variables (including molecular pathology data and information regarding toxicities) may restrict the extent of analyses feasible. Conclusion: There is scope to conduct large cohort studies to generate results from clinical practice using linkage of routinely collected health care data within a reasonable time frame; however, close collaboration between researchers, data controllers, and clinicians is required in order to obtain valid and meaningful results.

show abstract

Association between atopic dermatitis and colorectal cancer risk

Cited by 16 publications

References 42 publications

Autoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation

Autoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation

Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer

Opportunities and challenges when using record linkage of routinely collected electronic health care data to evaluate outcomes of systemic anti-cancer treatment in clinical practice

Contact Info

Product

Resources

About